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Case Study 
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long-term warning 
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Deagostini, Carlo Albera, Dario Roccatello and Antonio Bertolotto 
 
Abstract 
We report on a so-far never described association between glomerulonephritis and sarcoid-like lung 
disease after longterminterferon beta (IFNb) treatment for relapsing–remitting multiple sclerosis. 
The interest in this case resides in the documented remission after IFNb discontinuation. The 
history of IFNb-related adverse events is probably not yet completely written. The rapid reversal of 
the pathological signs in our patient underlines the importance of careful clinical and laboratory 
surveillance, including kidney functional parameters, for an early diagnosis of IFNb-related 
diseases. 
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Interferon beta (IFNb) is one of the first-line treatments for relapsing–remitting multiple sclerosis 
(RRMS). Despite its well-known efficacy and long-term tolerability, in the last decade a growing 
number of reports have associated longterm IFNb therapy with the development of autoimmune 
diseases, ranging from systemic lupus erythematosus to sarcoidosis and glomerulonephritis. 
Nevertheless, the pathogenic bases of the IFNb-related autoimmune derangements have not yet 
been completely elucidated (1-4). 
In this context, we would like to report on a so-far never described association between 
glomerulonephritis and sarcoid-like lung disease after long-term IFNb treatment for RRMS. 
The interest in this case also resides in the documented remission after IFNb discontinuation. 
 
Case report 
In January 1996, a 22-year-old woman developed sub-acute diplopia, and the diagnostic work-up 
revealed multiple T2+ lesions on brain MRI, cerebrospinal fluid positive for oligoclonal bands and 
altered somatosensory evoked potentials, suggesting the possibility of MS. She was treated with 
high-dose i.v. steroids which resulted in remission of the symptoms. After a clinical relapse in 1998 
RRMS was diagnosed, and she was started on intramuscular IFNb-1a (30 mcg per week) which was 
administered until March 2003, when she developed a severe clinical relapse involving the 
midbrain and spinal cord. 
A concomitant increase in lesion load was observed at brain MRI. Steroid pulses resulted in 
remission (Expanded Disability Status Scale (EDSS) 1.0). She was then switched to a higher dose 
of subcutaneous IFNb-1a (44 mcg three times a week), which was continued until June 2011, 
with complete control of disease activity (no clinical relapses, no increase in lesion load at brain 
MRI, EDSS 1.0). Blood tests and clinical evaluations were carried out every 6 months throughout 
the treatment period. Neutralizing antibodies to IFN tested negative, and in vivo MxA mRNA 
quantification demonstrated a good biological drug activity. In June 2011, she complained of 
arthralgia and peripheral oedema. Mild hypertension was observed during her clinical examination. 
Kidney function was normal, urinalysis showed proteinuria and microhematuria, while 24-h 
proteinuria ranged from 0.8–1.2 g/day. Abdominal ultrasound showed normal-sized kidneys with 
non-specific bilateral pyramidal hyperechogenicity. During the work-up prior to kidney biopsy, the 
incidental finding of non-specific derangement of the lung architecture led us to perform thorax CT 
scan which showed diffuse bronchial wall thickening, bronchiectasias in the lower lobes and 
enlarged paratracheal lymphnodes. A PET-CT scan showed bilateral pulmonary parenchymal 
hypercaptation, and foci in the spleen and at the hepatic hilium. Percutaneous kidney biopsy 
demonstrated thrombotic microangiopathy, glomerular basement membrane reduplication, signs of 
mesangiolysis and podocyte hypertrophy. Interestingly, the disease appeared to be limited to the 
kidney as the patient was not anaemic, serum bilirubin was normal and there were no signs of 
haemolysis. Complete auto-Abs panel tested negative. Both the kidney and lung diseases were 
considered to be IFNb-related. On account of the stable neurological picture, IFNb-1a was 
discontinued. In the following 6 months the patient remained in neurological remission, proteinuria 
progressively decreased to 0.33 g/day and PET-CT scan showed complete clearing of the 
sarcoidlike 
pattern (Figure 1). 
Discussion 
IFNb, a type I IFN, is a central regulator of systemic immunity, inducing several genes in both 
innate and adaptive immune cells by binding to specific receptors and modulating several 
IFNstimulated 
genes. The pro- and anti-inflammatory IFNb signature should depend upon the genetic 
background of each patient and the disease phase. The proinflammatory effect of IFNb may lead to 
the development or exacerbation of autoimmune diseases, and in particular those mediated by Th17 
(5). The rising number of reports on the onset of autoimmune diseases after IFNb therapy suggests 
that long-term remissions may merge into an over-activation of the immune system. This may be 
the case in our patient, who experienced a long-term remission of RRMS but developed a complex 
autoimmune systemic disease. Possibly on account of the early diagnosis, and despite the 
substantial morphological kidney damage and the diffuse lung involvement, our patient was only 
mildly symptomatic and achieved remission of proteinuria and complete clearing of the lung lesions 
after IFNb discontinuation. 
The association between sarcoidosis, glomerular and endothelial lesions and IFNb therapy is 
intriguing, and to the best of our knowledge, it has never been reported before. We did not look for 
complement genetic abnormalities that could be involved in the pathophysiology of thrombotic 
microangiopathy, although this seems unlikely owing to the remission of the diseases upon IFN 
discontinuation. Our case suggests testing the hypothesis that the endothelial and podocyte injury 
and the lung disease share a common pathogenic factor. A potential culprit may be interleukin 17 
(IL17), as sarcoidosis has recently been described as a Th1/Th17 multisystem disorder, while IL17 
has been implicated in the pathogenesis of glomerular sclerosis and of autoimmune 
thrombocytopenia within complex cytokine and cellular derangements (5-8). The history of 
IFNbrelated 
adverse events is probably not yet completely written. The rapid reversal of the pathological 
signs in our patient underlines the importance of careful clinical and laboratory surveillance, 
including kidney functional parameters, for an early diagnosis of IFNb-related diseases. 
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Figure 1. A) multiple areas of inhomogeneous increased fluoro-dexosi glucose (FDG) uptake in both lungs (SUV max: 
4.4) and increased tracer uptake in mediastinal and hilar lymph nodes; B) complete disappearance of abnormal tracer 
uptake in the thorax, resulting in a negative FDG PET scan. Please go to: www.http://msj.sagepub.com/ for colour 
plates. 
